Copyright
©The Author(s) 2022.
World J Clin Cases. Sep 16, 2022; 10(26): 9417-9427
Published online Sep 16, 2022. doi: 10.12998/wjcc.v10.i26.9417
Published online Sep 16, 2022. doi: 10.12998/wjcc.v10.i26.9417
Table 1 Main laboratory test results
| Laboratory tests | Result | Reference value |
| White blood cell count | 1.80 × 109/L | 3.5-9.5 × 109/L |
| Neutrophil count | 1.33 × 109/L | 1.8-6.3 × 109/L |
| Neutrophil percentage | 0.738 | 40-75% |
| Haemoglobin | 71 g/L | 115-150 g/L |
| Platelet count | 54 × 109/L | 100-300 × 109/L |
| Albumin | 26.5 g/L | 40.0-55.0 g/L |
| Lactate dehydrogenase | 347 IU/L | 120-250 IU/L |
| Erythrocyte sedimentation rate | 3.0 mm/h | < 38 mm/h |
| Coagulation function revealed a prothrombin time of | 18.2 s | 9.6-12.8 s |
| Fibrinogen | 0.64 g/L | 2.0-4.0 g/L |
Table 2 Immunohistochemistry of pleural fluid, ascites, liver, and bone marrow
| Parameter | Marrow | Ascites | Hydrothorax | Liver |
| CD2 | ++ | + | + | - |
| CD3 | ++ | ++ | + | + |
| CD4 | - | - | - | - |
| CD5 | + | + | + | |
| CD7 | ++ | ++ | ++ | + |
| CD8 | + | + | ++ | + |
| CD11c | - | - | ||
| CD16 | - | + | - | |
| CD30 | - | |||
| CD34 | - | |||
| CD38 | - | ++ | ||
| CD43 | + | |||
| CD45 | + | |||
| CD56 | ++ | ++ | ++ | + |
| CD57 | + | +p | ++ | |
| TCRαβ | + | + | ||
| TCRγδ | - | - | ||
| TIA-1 | - | |||
| TDT | - | |||
| Ki-67 | + |
Table 3 A summary of demographic, radiographic, and clinical information from a review of five previously published cases of T-cell lymphomas with ascites and/or portal hypertension manifestations
| Ref. | Age, Gender | Course of disease | Clinical Symptoms | Supplementary Examination | Biopsy Source | Immunohistochemistry | Diagnosis | Invasion of other parts | Treatment | Prognosis |
| Ameri[13] | 61, F | 2+W | Abdominal discomfort | Ascites, hepatosplenomegaly | Ascites | CD4(+), CD2(+), CD5(+), CD3(+), CD7(-), CD16(-), CD56(-), CD57(-), TdT(-) | PTCL, NOS | Bone marrow | No treatment | NA |
| Yamamoto[10] | 72, W | 3+W | Abdominal discomfort | Hydrothorax and ascites | Ascites | CD2 (+), CD3(+) (+),CD45(+), CD4 (–), CD8 (–) | PTCL | Thorax and abdomen | Cyclophosphamide, mitoxantrone, vincristine, etoposide, bleomycin, and prednisolone | Died of multiple organ failure |
| Izban[12] | 76, F | Abdominal tenderness | Ascites, splenomegaly | Ascites | CD2(+), CD3(+), CD5(+), CD7(+), CD45(+), CD4(-), CD8(-) | PTCL | Bone marrow, liver | CHOP chemotherapy | Recurrence after chemotherapy | |
| VakarLópez[11] | 49, W | 3+M | Abdominal tenderness | Ascites | Ascites | CD3(+) | PTCL, NOS | No treatment | NA | |
| Lindor[9] | 65, F | 2+Y | Pectoralgia, esophageal and gastric variceal bleeding (EGVB) | Splenomegaly, EGVB | spleen | NA | Diffuse mixed-type T-cell lymphoma | Splenectomy | Bone marrow infiltration occurred 1 + year after the operation | |
- Citation: Wu MM, Fu WJ, Wu J, Zhu LL, Niu T, Yang R, Yao J, Lu Q, Liao XY. Noncirrhotic portal hypertension due to peripheral T-cell lymphoma, not otherwise specified: A case report. World J Clin Cases 2022; 10(26): 9417-9427
- URL: https://www.wjgnet.com/2307-8960/full/v10/i26/9417.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i26.9417
